Finance

Lists
GRF:BME
Grifols SA Class A
€11.65
-0.09%
(-0.010) 1D
Nov 13, 5:44:58 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GRF...
Open
€11.67
High
€11.70
Low
€11.56
Mkt. cap
7.11B
Avg. vol.
1.86M
Volume
1.27M
Dividend
1.99%
Quarterly dividend
€0.06
Ex-dividend date
Dec 2, 2026
P/E ratio
16.39
52-wk high
€11.70
52-wk low
€8.43
EPS
€0.71
Shares outstanding
426.13M
No. of employees
25K
Open
€11.67
High
€11.70
Low
€11.56
Mkt. cap
7.11B
Avg. vol.
1.86M
Volume
1.27M
Dividend
1.99%
Quarterly dividend
€0.06
Ex-dividend date
Dec 2, 2026
P/E ratio
16.39
52-wk high
€11.70
52-wk low
€8.43
EPS
€0.71
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A
CEONacho Abia
Employees25K
FoundedNov 18, 1940
Headquarters-
SectorHealth Care
IndustryBiotechnology
Last report
Nov 2, 2026
Fiscal period
Q3 2026
- / €0.27
Revenue / Est. (EUR)
2.04B / 1.98B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.98B
1.70B
1.87B
2.04B
Cost of goods sold
1.28B
1.06B
1.19B
1.22B
Cost of revenue
1.28B
1.06B
1.19B
1.22B
Research and development expenses
90.82M
90.00M
86.00M
87.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
262.86M
269.00M
301.00M
301.00M
Operating expense
353.11M
359.00M
387.00M
388.00M
Total operating expenses
1.63B
1.42B
1.58B
1.61B
Operating income
347.38M
280.00M
298.00M
431.00M
Other non operating income
-33.00M
-
-13.00M
-1.00M
EBT including unusual items
111.10M
112.00M
247.00M
238.00M
EBT excluding unusual items
183.10M
143.00M
216.00M
275.00M
Income tax expense
-14.68M
24.00M
64.00M
57.00M
Effective tax rate
-13.21%
21.43%
25.91%
23.95%
Other operating expenses
-570.00K
-
-
-
Net income
98.25M
73.00M
154.00M
162.00M
Net profit margin
4.96%
4.29%
8.22%
7.94%
Earnings per share
-
-
-
-
Interest and investment income
36.00M
-
120.00M
-
Interest expense
-107.99M
-139.00M
-179.00M
-153.00M
Net interest expenses
-71.99M
-139.00M
-59.00M
-153.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
422.88M
384.00M
364.00M
545.00M
Gain or loss from assets sale
2.00M
-
-6.00M
-
Upcoming events
AI content may include mistakes. Learn more
Google apps